Is CE a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Deleveraging through cash and asset sales, with revenue (ttm) at ~$9.7B. The bear case rests on leverage dominates the risk list. Analysts covering it are spread from $45.00 to $86.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Leverage dominates the risk list. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $45.00, +1.2% from the $44.46 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Deleveraging through cash and asset sales. Every capital-allocation lever Celanese has pulled since late 2024 points the same direction: a ~95% dividend cut, a paused repurchase program, reduced capital spending at roughly ~$128M in the first half of 2026, and the ~$493M Micromax sale to Element Solutions that closed in February. The most optimistic analyst target on CE is $86.00, +93.4% from the $44.46 price. That figure is only reachable if this thesis works close to its best case.

Leverage dominates the risk list. Total debt of roughly ~$12.0B against about ~$4.6B of book equity leaves a debt-to-equity ratio near ~2.7 and an enterprise value of roughly ~$16.3B against a ~$4.8B market cap, so a modest change in enterprise value swings the equity hard in either direction. Celanese amended financial ratio maintenance covenants in its U.S. credit facilities during 2025 and again on July 31, 2026, and while it was in compliance as of June 30, 2026 and expects to remain so, its own filing notes that results materially below expectation could require seeking a further amendment or waiver. On the legal side, follow-on damages claims arising from the company's July 2020 settlement of a European Commission ethylene-purchasing competition investigation remain live: ~14 claims have been filed since 2023 by parties including Shell, Repsol entities, BASF, Dow, ExxonMobil, BP, MOL Group and Braskem in the District Court of Amsterdam and the German courts of Munich and Dortmund, and on July 30, 2026 the Amsterdam court dismissed the Shell and Repsol claims in their entirety as not plausible, a ruling subject to appeal. Celanese states it cannot estimate the potential impact of the remaining matters. Several plaintiff law firms announced investigations of potential securities claims after the November 2024 earnings and guidance disappointment, though no filed securities class action appears in the company's Legal Proceedings disclosure, and the auditors have raised no going-concern doubt. The most pessimistic published target is $45.00, +1.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Celanese makes chemicals in two very different businesses, engineered polymers sold into autos and electronics, and commodity acetyls.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Deleveraging through cash and asset sales) stalling in the reported numbers rather than in the narrative, the risk above (leverage dominates the risk list) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Two segments split the business. Acetyl Chain produces acetic acid, vinyl acetate monomer, acetate tow and derivatives sold as intermediates into paints, adhesives, textiles and filters. Engineered Materials sells specialty polymers, nylon, elastomers and compounds designed into automotive parts, medical devices, electronics and industrial equipment, and it was the larger half at roughly ~$2.8B of first-half 2026 sales.

Debt absorbs most of the enterprise. Celanese carries about ~$12.0B of total debt against roughly ~$1.4B of cash, so an enterprise value near ~$16.3B leaves only about ~$4.8B for shareholders. Revenue of ~$9.7B belongs to the whole capital structure, not to the equity, which is why price to sales of ~0.5x and enterprise value to sales of ~1.7x tell such different stories about the same company.

Financing the 2022 purchase of DuPont's Mobility and Materials business, at roughly ~$11B, added the bulk of the borrowings. Automotive and European industrial demand then weakened for several consecutive years, so the acquired earnings arrived well below the level assumed at the time. Goodwill impairments in Engineered Materials now total ~$2.7B of accumulated write-downs, which is the accounting record of that gap.